Evaluation of WHO Criteria for Viral Failure in Patients on Antiretroviral Treatment in Resource-Limited Settings

Table 1

Comparison of the baseline characteristics of 473 patients classified in three groups according to their level of viremia.

Patients characteristics	Sustained suppression* 336 (71.0%)	Intermediate viremia* 53 (11.2)	High viremia* 84 (17.8)	P value
Female, number (%)	240 (71.4)	30 (56.6)	56 (66.7)	.085
Age (years), median (IQR)	35 (30–42)	34 (30–42)	34 (28–38.5)	.168
CD4+ count median cell/𝜇L (IQR)	107 (35–174)	85 (25–154)	89.5 (26–165)	.246
BMI (Kg/m^2), median IQR	20.1 (18.3–22.5)	20.6 (18.5–20.5)	20.0 (18–22.5)	.816
WHO Stage 3 and 4, number (%)	291 (86.6)	51 (96.2)	76 (90.5)	.102
Hemoglobin median g/dL (IQR)	11.7 (10.4–13)	11.9 (10.8–13.2)	11.6 (10.5–13)	.792
ART, number (%); Nevirapine	241 (71.7)	48 (90.6)	61 (72.6)	.009
Efavirenz	95 (28.3)	5 (9.4)	23 (27.4)

*Patients were categorized according to viral load measurements after 6 months on treatment. (1) Sustained suppression. Viral load ≤1,000 copies/mL at each measurement. (2) Subjects with a first episode of intermediate viremia. Viral load between 1,001–10,000 copies/mL. (3) Subjects with a first episode of high viremia. Viral load >10,000 copies/mL.
BMI: body mass index; ART: antiretroviral treatment; IQR: interquartile range.